Rallybio reports FY2022 net loss of $66.7M; RLYB212 achieves proof-of-concept in Phase 1b

Rallybio Corp

Net loss for FY2022 was $66.7M ($2.09/share) vs $47.0M ($1.84/share) in 2021; Q4 loss $16.2M.
RLYB212 Phase 1b proof-of-concept: single dose eliminated >90% of HPA-1a positive platelets; well-tolerated.
Cash, equivalents, and marketable securities $169.0M as of Dec 31, 2022; runway into Q1 2025.
RLYB211 discontinued; RLYB212 multi-dose cohort initiated, data expected Q4 2023.
Jonathan Lieber appointed CFO effective Feb 1, 2023; follow-on offering raised ~$55M in Nov 2022.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Rallybio Corp reported financial results for the fourth quarter and full year ended December 31, 2022.

Period: the fourth quarter and full year ended December 31, 2022
Result: reported results

Exact text from the filing

On March 6, 2023, Rallybio Corporation issued a press release announcing its financial results for the quarter and year ended December 31, 2022.

View on SEC.gov

Browse all earnings releases →

Rallybio Corp filing history →

Source: SEC EDGAR

accession 0000950170-23-006125

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.